# FutureTech II Acquisition Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/FutureTech II Acquisition Corp.). ## Overview FutureTech II Acquisition Corp. is a Delaware-incorporated blank check company formed to complete a merger, stock exchange, asset acquisition, or similar business combination. It has no operating business of its own and is focused on identifying and closing a transaction, with the current disclosed target being Longevity Biomedical, Inc. ## Products & services • Special purpose acquisition company (SPAC) structure • Business combination / merger execution • Public listing and capital-raising vehicle • PIPE/private placement financing support • Trust account management for redemption protection - **SPAC formation and listing vehicle** (0%) — A publicly traded shell company created to raise capital and pursue a future acquisition. - **Business combination execution** (0%) — Transaction structuring and closing activities related to a proposed merger or acquisition. - **Private placement and financing support** (0%) — PIPE-style capital commitments and related financing arrangements tied to the transaction. - **Trust account administration** (0%) — Management of IPO proceeds held in trust for shareholder redemptions and deal funding. - Special purpose acquisition company (SPAC) structure - Business combination / merger execution - Public listing and capital-raising vehicle - PIPE/private placement financing support - Trust account management for redemption protection ## Customers The company does not sell products or services to end customers in the normal operating sense. Its stakeholders are IPO investors, public shareholders, warrant holders, and potential merger counterparties such as Longevity Biomedical, Inc. The business model depends on attracting a suitable target and securing enough financing and shareholder support to complete the transaction. - **Public shareholders** (primary) — Invest in the SPAC for redemption rights and potential upside if a business combination closes. - **Merger target company** (primary) — The target, currently disclosed as Longevity Biomedical, Inc., is the core counterparty for the business combination. - **PIPE investors** (secondary) — Provide private placement capital to support the merger and post-close capitalization. - **Warrant holders** (secondary) — Hold optionality on the combined company’s equity value after the transaction. - Public shareholders who hold redeemable Class A shares - Warrant holders seeking upside from a completed deal - PIPE investors providing transaction financing - Merger target companies looking for a public listing path - Underwriters and financing counterparties tied to closing ## Geography FutureTech II Acquisition Corp. is incorporated in Delaware and operates as a U.S.-based capital markets vehicle. The available filings do not disclose operating revenue by geography because the company has no commercial operations; its exposure is primarily to U.S. securities markets, Nasdaq listing status, and the location of its merger target and financing counterparties. - Incorporated in Delaware, United States - No operating revenue or manufacturing footprint disclosed - Exposure is tied to U.S. capital markets and listing venues - Transaction counterparties may be U.S.-based or international - Geography matters mainly through regulatory and financing access ## Strategy The company’s strategy is to complete its announced business combination and secure the financing needed to close it. Recent disclosures show continued work on a PIPE subscription, redemption management, and extension of the business combination deadline, all of which are aimed at preserving deal optionality and closing conditions. - **Complete the Longevity Biomedical merger** (short-term) — The company has no operating business until a transaction closes, so execution is existential. - **Secure financing support** (short-term) — The deal depends on sufficient capital at closing and post-close funding credibility. - **Preserve public market access** (short-term) — Listing status affects redemption dynamics, financing access, and merger completion probability. - Close the proposed Longevity Biomedical business combination - Use PIPE capital to strengthen the post-close balance sheet - Manage redemptions to preserve transaction viability - Extend the deadline to keep the deal process alive - Maintain listing access to support closing and liquidity ## Risks The main risk is that the company may fail to complete its business combination, which would leave it without an operating business and could force liquidation or value loss. It also faces redemption pressure, listing risk, and financing risk, all of which can reduce the cash available for closing and weaken the attractiveness of the transaction to counterparties. - **Failure to consummate the business combination** [critical] — The company is a blank check entity with no operating business, so failure to close would leave it without a commercial platform. - **Redemptions reduce transaction cash** [high] — Shareholder redemptions shrink the trust balance and can make the deal harder to finance. - **Listing and marketability risk** [high] — OTC Pink trading or Nasdaq delisting can reduce liquidity, financing access, and merger credibility. - **Trust account and third-party claim risk** [medium] — Claims against the trust account could reduce funds otherwise available for redemption or closing. - Failure to close the Longevity Biomedical transaction - High redemption levels reduce cash available at closing - Nasdaq delisting or OTC Pink trading can impair financing - Trust account claims or disputes could reduce protected cash - No operating revenue means continued dependence on capital ## Accounting Accounting is dominated by SPAC-specific judgments rather than operating revenue recognition. Key areas include redeemable Class A share classification, accretion to redemption value, deferred underwriting fees, and fair value/estimate judgments around transaction-related liabilities and financing arrangements. - **Redeemable Class A common stock** — Accretion to redemption value and balance sheet presentation - **Deferred underwriting commission** — Closing-dependent liability and transaction accounting - **Accretion to redemption value** — Non-cash charge affecting earnings and shareholders' equity - **Estimates and assumptions** — Reported liabilities and expenses may change materially - Redeemable shares require liability/equity classification judgments - Accretion to redemption value affects balance sheet and equity - Deferred underwriting commission is contingent on closing - PIPE and merger-related notes depend on transaction completion - Estimates and fair value judgments affect reported liabilities --- *Last updated: 2026-04-28T20:09:21.296601+00:00*